Recce Pharmaceuticals Ltd Share Price OTC Markets
Stocks
RECEF
AU000000RCE5
Pharmaceuticals
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2200 USD | -56.00% |
|
-.--% | - |
| 07-30 | Recce Pharmaceuticals in Position to Benefit from US ASPR Medical Countermeasures Strategy | MT |
| 07-21 | Recce Pharmaceuticals Reports Higher Cash Balance in June Quarter | MT |
| Market Cap | 111M 77.78M 67.61M 62.93M 57.78M 109M 7.42B 742M 291M 3.7B 292M 286M 12.39B | P/E 2026 * |
-6.07x | P/E 2027 * | -4.35x |
|---|---|---|---|---|---|
| Enterprise Value | 116M 81.45M 70.81M 65.91M 60.51M 114M 7.78B 777M 305M 3.87B 306M 299M 12.98B | EV / Sales 2026 * |
14.9x | EV / Sales 2027 * | 10.9x |
| Free-Float |
60.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| 1 day | -56.00% |
| 3 years | 0.22 |  | 0.6 |
| 5 years | 0.22 | | 0.6 |
| 10 years | 0.22 | | 0.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
James Graham
CEO | Chief Executive Officer | - | 27/08/2020 |
Justin Reynolds
DFI | Director of Finance/CFO | - | - |
Michele Dilizia
CTO | Chief Tech/Sci/R&D Officer | - | 29/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
Michele Dilizia
BRD | Director/Board Member | - | 30/09/2012 |
James Graham
BRD | Director/Board Member | - | 30/04/2012 |
| Director/Board Member | - | 31/08/2022 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -56.00% | -.--% | - | - | 77.78M | |
| -0.53% | -3.95% | +50.70% | +153.56% | 1,024B | |
| +0.21% | -2.68% | +53.20% | +51.79% | 618B | |
| -2.51% | -3.25% | +28.54% | +68.94% | 443B | |
| +0.06% | -0.42% | +37.53% | +30.67% | 349B | |
| -0.69% | -0.30% | +13.76% | +12.83% | 264B | |
| -7.37% | -4.40% | -0.74% | -44.28% | 209B | |
| -0.64% | +2.43% | +29.74% | +65.93% | 208B | |
| -0.82% | +0.70% | +15.05% | +72.05% | 162B | |
| +0.40% | +1.92% | +6.47% | -29.77% | 143B | |
| Average | -6.79% | -1.21% | +26.03% | +42.41% | 379.88B | |
| Weighted average by Cap. | -1.01% | -2.02% | +36.14% | +71.90% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 7.78M 5.46M 4.75M 4.42M 4.06M 7.66M 521M 52.08M 20.44M 260M 20.51M 20.06M 870M | 12.5M 8.77M 7.62M 7.1M 6.52M 12.3M 837M 83.66M 32.83M 417M 32.94M 32.22M 1.4B |
| Net income | -18.29M -12.84M -11.16M -10.39M -9.54M -18.01M -1.23B -122M -48.06M -610M -48.22M -47.16M -2.05B | -25.1M -17.62M -15.32M -14.26M -13.09M -24.72M -1.68B -168M -65.95M -837M -66.17M -64.71M -2.81B |
| Net Debt | 5.24M 3.67M 3.19M 2.97M 2.73M 5.16M 351M 35.05M 13.76M 175M 13.8M 13.5M 586M | 24.96M 17.52M 15.23M 14.18M 13.02M 24.58M 1.67B 167M 65.59M 833M 65.81M 64.36M 2.79B |
Employees
-
Sector
Pharmaceuticals
Annual profits - Rate of surprise
- Stock Market
- Stocks
- RCE Stock
- RECEF Stock
Select your edition
All financial news and data tailored to specific country editions
